Skip to main content

Table 2 Univariate and multivariate analyses for survival outcomes in whole study population

From: Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles

Characteristics

Progression-free survival

Overall survival

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

HR

95% CI

aHR

95% CI

P

HR

95% CI

aHR

95% CI

P

Age at initial diagnosis, years

 ≥55 vs. <55

0.83

0.57–1.19

0.75

0.51–1.08

0.122

0.96

0.51–1.78

   

Histologic type

 Non-HGSC vs. HGSC

1.10

0.64–1.90

   

0.80

0.29–2.26

   

FIGO stage

 IV vs. I-III

1.15

0.77–1.71

0.81

0.53–1.22

0.308

0.98

0.48–2.00

0.78

0.37–1.66

0.515

Primary treatment strategy

 NAC vs. PDS

0.92

0.60–1.39

   

2.28

1.20–4.34

   

Results of initial debulking surgery

 Residual tumor vs. CGR

1.16

0.81–1.66

   

1.26

0.68–2.36

   

Platinum-free interval, months

 ≥12 vs. 6–12

0.46

0.31–0.66

0.42

0.29–0.63

<0.001

0.36

0.19–0.67

0.37

0.19–0.70

0.003

CA-125 at 1st recurrence, IU/mL

 ≥90 vs. <90

1.76

1.22–2.53

2.21

1.50–3.25

<0.001

1.92

1.02–3.60

1.90

1.00–3.60

0.050

Secondary debulking surgery

 Yes vs. No

0.67

0.37–1.22

   

0.88

0.27–2.88

   

Residual tumor on CT after #6

 ≥1 cm vs. <1 cm

1.09

0.76–1.56

1.20

0.83–1.74

0.326

2.01

1.04–3.90

2.38

1.20–4.71

0.013

CA-125 after #6, IU/mL

 ≥12.5 vs. <12.5

1.50

1.04–2.15

   

1.47

0.79–2.73

   

Maintenance therapy

 Yes vs. No

0.50

0.32–0.76

0.44

0.28–0.69

<0.001

0.67

0.30–1.53

0.65

0.28–1.52

0.317

Extended chemotherapy

 Yes vs. No

1.61

1.11–2.34

1.25

0.84–1.85

0.279

1.32

0.71–2.44

1.36

0.72–2.56

0.342

  1. Abbreviations: aHR Adjusted HR, CA-125 Cancer antigen 125, CGR Complete gross resection, CI Confidence interval, CT Computed tomography, FIGO International Federation of Gynecology and Obstetrics, HGSC High-grade serous carcinoma, HR Hazard ratio